Skip to main content
BIO·ATLASby Bayes Pharma.ai
Search
AccountStart evaluation
AI drug discovery models/AI-Native Discovery Cos./Exscientia
organization passport · Review date not recorded

Exscientia

The pioneer of AI-designed small molecules in the clinic.

1/7Evidence fields documented
60-SECOND EVALUATION VIEW

What should a scientist know before using Exscientia?

UnresolvedEvidence direction is incomplete or not yet resolved
Best suited forPlatform · Discovery
Evidence supportsPrimary links may be present, but BioAtlas does not claim a review date without a record-level timestamp.
Evidence does not establishUniversal superiority, therapeutic success, clinical utility or regulatory acceptance.
Major limitationIndependent reproducibility is limited by proprietary access.
CompareAdd to evaluationView evidence
Current registry recordVersion history pending0 recorded releases · Review date not recorded. A newer version is not assumed to be universally better.

What it is

Exscientia was among the first to put AI-designed small molecules into human trials, using active-learning design and a 'Centaur Chemist' human-in-the-loop workflow plus patient-tissue precision models. Recursion completed its acquisition on 20 November 2024, making Exscientia a wholly owned subsidiary rather than an independent active startup.

Evidence trail

BioAtlas keeps the path from source to decision visible. A connection records provenance; it does not imply that evidence is sufficient for every context.

Sources2 connectedPrimary resources and normalized claims
Claims0 normalizedNo normalized claim yet
EntityExscientiaorganization · Version history pending
ReviewReview date not recordedReview date not claimed
ConclusionContext requiredAdd to an evaluation before operational use

Model passport

Entity typeorganization
OrganizationRecursion Pharmaceuticals
Organization founded2012
AccessProprietary
Commercial useVendor terms
DeploymentVendor managed
ComputeVendor managed
Domainscompany
Biology → representation → computation → evidence

How Exscientia represents biology

organizationcompany

Category is navigation. These fields describe the model-specific computational transformation and deliberately override broad category defaults.

1 · Biological inputs
Disease hypothesis and multimodal evidence
2 · Input representation
Organization / platform dependent
3 · Internal representation
Multiple systems
4 · Architecture
Organization / discovery system
5 · Learning objective
Integrated discovery
6 · Output representation
Programs and evidence

Biological scale

Modalities & tasks

MultimodalPlatformDiscovery

Registry, claims and frontier intelligence

Versioned registry

Version history pending

0 version records · release year not yet normalized. Model-family identity remains separate from capability and access changes.

Explore version lineage →
Benchmark claim ledger

0 normalized claims

No task, dataset, split and metric claim has been normalized for this record yet.

Open claim intelligence →

Inputs and outputs

Inputs

Disease hypothesis and multimodal evidence

Outputs

Targets, candidates or development programs

Scientific and technical profile

Scientific principles

Active-learning molecule designHuman-in-the-loop chemistryPrecision oncology models

Technology

Generative chemistryAutomated design–make–testPatient-derived tissue assays
Ideas before algorithms

Scientific lineage

Explore all foundations

These are transparent concept matches—not claims that one scientist alone caused this model. Each connection is based on the model’s recorded domain, scientific principles, technical terms or an explicit lineage link.

Medicinal chemistry & pharmacology

Selective toxicity and the ‘magic bullet’

Paul Ehrlich

Target selectivity, therapeutic index and mechanism-based screening remain central goals of drug discovery.

Matched concepts: target
Medicinal chemistry & pharmacology

Rational antimetabolite drug design

Gertrude B. Elion & George H. Hitchings

Mechanism-based design, pathway selectivity and iterative medicinal chemistry are direct descendants of this strategy.

Matched concepts: candidate
Medicinal chemistry & pharmacology

Quantitative structure–activity relationships

Corwin Hansch

Classical QSAR established the central premise that molecular features can predict potency and guide optimization—the conceptual ancestor of modern molecular machine learning.

Matched concepts: molecule

Evaluation evidence

Dataset or evaluationNot yet curated
Task or metricNot yet extracted
Evidence statusNo task-specific benchmark record curated
Open source ↗

BioAtlas has not yet extracted a structured benchmark claim for this record.

Known limitations

  • Independent reproducibility is limited by proprietary access.
  • A structured benchmark claim has not yet been extracted for this record.
  • Outputs require task-specific scientific and experimental validation.

Milestones

2012

Among the first with AI-designed molecules in trials.

Evidence

Wholly owned by Recursion since 20 November 2024.